## **Core Concept**
Pulmonary hypertension (PH) is a condition characterized by elevated blood pressure in the pulmonary arteries, which can lead to right heart failure. The management of PH involves various pharmacological agents targeting different pathways to reduce pulmonary vascular resistance and improve symptoms.

## **Why the Correct Answer is Right**
The correct answer, , is not used in the treatment of pulmonary hypertension. In contrast, other options like endothelin receptor antagonists (e.g., bosentan), phosphodiesterase-5 inhibitors (e.g., sildenafil), prostacyclin analogs (e.g., epoprostenol), and soluble guanylate cyclase stimulators (e.g., riociguat) are established treatments for pulmonary hypertension.

## **Why Each Wrong Option is Incorrect**
* **Option A:** - This class of drugs, such as bosentan, is used in the treatment of pulmonary hypertension by blocking endothelin receptors, which are involved in vasoconstriction and vascular remodeling.
* **Option B:** - Drugs like sildenafil are used to treat pulmonary hypertension by inhibiting phosphodiesterase-5, which increases levels of cyclic GMP, leading to vasodilation.
* **Option C:** - Prostacyclin analogs, such as epoprostenol, are used in the treatment of advanced pulmonary hypertension. They work by mimicking the effects of prostacyclin, leading to vasodilation and inhibition of platelet aggregation.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that the management of pulmonary hypertension often involves a combination of these targeted therapies, and the choice of treatment depends on the patient's specific condition, symptoms, and response to therapy.

## **Correct Answer:** .